{"groups":[{"description":"Patients receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Treatment (Palbociclib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"16"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"No Treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"23"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"23"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}